The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1442
May 12, 2014
View Complete Issue         Table of Contents 2019 
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
May 12, 2014 (Issue: 1442)
The FDA has approved avanafil (Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication. Advertisements on Stendra’s website...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
Article code: 1442a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.